Key Takeaways The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, as the Federal Reserve announced its first interest-rate ...

Major U.S. indexes were little changed at midday Wednesday, ahead of the Federal Reserve's decision on interest rates.

Wolfe Research analyst Michael Polark downgraded the rating on Resmed (RMD – Research Report) to a Sell yesterday, setting a price target ...

Shares of ResMed Inc. RMD inched 0.81% higher to $244.94 Friday, on what proved to be an all-around mixed trading session for ...

Wolfe Research has recently reduced Resmed Inc (RMD) stock to Underperform rating, as announced on September 18, 2024, according to Finviz. Earlier, on September 4, 2024, Needham had reduced the stock ...

Healthcare technology company ResMed's (NYSE: RMD) stock wasn't quite the picture of health on Wednesday. The shares lost ...

ResMed achieved double-digit revenue growth through acquisitions and operating efficiencies, with improving capital ...

ResMed's AirSense 11 platform and myAir app enhance patient engagement and efficiency. Check out why I remain bullish on RMD ...

In a report released today, Michael Matson from Needham maintained a Hold rating on Resmed (RMD – Research Report). The company’s ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

ResMed RMD has outperformed the market over the past 15 years by 5.67% on an annualized basis producing an average annual ...

ResMed faces a 3% drop in share price after concerns over Eli Lilly’s Ozempic, which could impact the demand for CPAP ...